We are live on ! Find out more
SLNO

Soleno Therapeutics

Delisted

SLNO was delisted on the 15th of May, 2026.

142 hedge funds and large institutions have $2.38B invested in Soleno Therapeutics in 2024 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 57 increasing their positions, 28 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 14

104% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 28

85% more call options, than puts

Call options by funds: $44.5M | Put options by funds: $24M

33% more capital invested

Capital invested by funds: $1.79B → $2.38B (+$589M)

25% more funds holding

Funds holding: 114142 (+28)

0.75% more ownership

Funds ownership: 120.48%121.22% (+0.75%)

10% less funds holding in top 10

Funds holding in top 10: 109 (-1)

Holders
142
Holders Change
+28
Holders Change %
+24.56%
% of All Funds
2.04%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.13%
New
42
Increased
57
Reduced
28
Closed
14
Calls
$44.5M
Puts
$24M
Net Calls
+$20.5M
Net Calls Change
+$34M
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
151
Aquatic Capital Management
Illinois
-$36.7K -900 Closed
Pacer Advisors
152
Pacer Advisors
Pennsylvania
-$12.5K -307 Closed
VAG
153
VisionPoint Advisory Group
Texas
-$6.85K -168 Closed
Group One Trading
154
Group One Trading
Illinois
-$1.77K -37 Closed
C
155
Covestor
United Kingdom
+$96 +2 New
CAL
156
Capital Advisors Ltd
Ohio
+$287 +6 New

SLNO Hedge Fund Activity: Q3 2024 in Review

142 of the 6,971 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2024, worth a combined $2.38B — up 33% from $1.79B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new SLNO positions and 14 closed out — a net gain of 28 holders — while 57 added to existing stakes and 28 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $46.7M. The largest seller was Vivo Capital, cutting an estimated $49.1M.

  • 142 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2024, up from 114 in Q2 2024.
  • Funds reported $2.38B of Soleno Therapeutics stock for Q3 2024, up 33% quarter-over-quarter.
  • 42 funds opened new Soleno Therapeutics positions in Q3 2024 and 14 closed out, a net change of +28 holders.
  • The largest Soleno Therapeutics buyer in Q3 2024 was Alyeska Investment Group, an estimated $46.7M added.
  • The largest Soleno Therapeutics seller in Q3 2024 was Vivo Capital, an estimated $49.1M sold.

Based on aggregated 13F filings for Q3 2024.